Hepatocyte growth factor (HGF) is a polypeptide with mitogenic, motogenic, and morphogenic eects on dierent cell types including hepatocytes. HGF is expressed as two biologically active isotypes resulting from alternative RNA splicing. The roles of each HGF isoform in development, liver regeneration and tumorigenesis have not yet been well characterized. We report the generation and analysis of transgenic mice overexpressing the ®ve amino acid-deleted variant of HGF (dHGF) in the liver by virtue of an albumin expression vector. These ALB-dHGF transgenic mice develop normally, have an enhanced rate of liver regeneration after partial hepatectomy, and exhibit a threefold higher incidence of hepatocellular carcinoma (HCC) beyond 17 months of age. Moreover, overexpression of dHGF dramatically accelerates diethyl-nitrosamine induced HCC tumorigenesis. These tumors arise faster, are signi®cantly larger, more numerous and more invasive than those appearing in non-transgenic littermates. Approximately 90% of female dHGF-transgenic mice had multiple macroscopic HCCs 40 weeks after injection of DEN; whereas the non-transgenic counterparts had only microscopic nodules. Liver tumors and cultured tumor cell lines from dHGF transgenics showed high levels of HGF and c-Met mRNA and protein. Together, these results reveal that in vivo dHGF plays an active role in liver regeneration and HCC tumorigenesis.
Hepatocyte growth factor (HGF) is a polypeptide with mitogenic, motogenic, and morphogenic eects on dierent cell types including hepatocytes. HGF is expressed as two biologically active isotypes resulting from alternative RNA splicing. The roles of each HGF isoform in development, liver regeneration and tumorigenesis have not yet been well characterized. We report the generation and analysis of transgenic mice overexpressing the ®ve amino acid-deleted variant of HGF (dHGF) in the liver by virtue of an albumin expression vector. These ALB-dHGF transgenic mice develop normally, have an enhanced rate of liver regeneration after partial hepatectomy, and exhibit a threefold higher incidence of hepatocellular carcinoma (HCC) beyond 17 months of age. Moreover, overexpression of dHGF dramatically accelerates diethyl-nitrosamine induced
Introduction
Hepatocyte growth factor (HGF) is a heparin binding glycoprotein originally puri®ed from serum and platelets based on its ability to induce a mitogenic response in normal hepatocytes in primary culture (Gohda et al., 1988; Nakamura et al., 1986; Zarnegar and Michalopoulos, 1989) . Molecular cloning of the full length human, rat and mouse HGF-cDNAs has shown that the protein is encoded by a single open reading frame with highly conserved amino acids (Liu et al., 1994a; Miyazawa et al., 1991; Nakamura et al., 1989; Okajima et al., 1990) . These studies revealed that HGF exists in two major biologically active isoforms: one that has 728 amino acids and another with 723 amino acids arising by alternative splicing of the primary RNA transcript. The latter, which contains an in-frame ®ve amino acid deletion in the ®rst kringle domain, was cloned from cDNAs prepared from various tissues such as human leukocytes, human embryonic lung ®broblasts, human placenta and rat liver. This isotype has been named dHGF Seki et al., 1990) . The in-frame deletion (amino acids 163 ± 167), although occurring in a domain responsible for receptor binding, does not result in loss of bioactivity in vitro (Shima et al., 1991 (Shima et al., , 1994 Yee et al., 1993) . In fact, dHGF has been shown to have enhanced mitogenic activity on several cell types including rat hepatocytes in comparison to the full length HGF (Shima et al., 1994) .
HGF and dHGF are also strong mitogens for other epithelial cell types as well as melanocytes and endothelial cells in vitro (Bussolino et al., 1992; Rubin et al., 1991) . In addition to mitogenesis, HGF and dHGF possess a diverse array of biologic activities including motogenesis and morphogenesis (Brinkmann et al., 1995; Chan et al., 1993; Stoker et al., 1987; Tsarfaty et al., 1992) . HGF and dHGF exert their biological eects on target cells through binding and stimulating a speci®c transmembrane tyrosine kinase cell surface receptor (HGFR) known as Met, the product of the proto-oncogene c-met Naldini et al., 1991; Rubin et al., 1993; Weidner et al., 1993) . This ligand receptor system is essential for the growth of various tissues such as liver during embryonic development Uehara et al., 1995) and is also believed to be an important paracrine mediator of mesenchymalepithelial interactions in organ regeneration and cancer (Tsarfaty et al., 1994) . In the present study, we investigated the role of dHGF in liver growth and carcinogenesis in transgenic mice using a gain-offunction model system (i.e. overexpression of dHGF in the liver).
Results

Generation of transgenic mice overexpressing dHGF in the liver
A transgenic expression construct containing the 2.3 kb coding region of the ®ve amino acid deleted isoform of human HGF (dHGF) cDNA under the transcriptional control of the mouse albumin promoter/enhancer was used to generate transgenic mice (Figure 1a) . Northern blot analysis showed that expression of the 2.3 kb transgene mRNA is directed to the liver and is present at levels 10 ± 20-fold higher than that of the endogenous 6 kb HGF mRNA (Figure 1b) which is known to contain approximately 4 kb of 3'-untranslated region (Nakamura et al., 1989) .
Although it is well known that HGF and dHGF are expressed in various tissues, the relative expression level of the full-length HGF (728 amino acid isoform) in comparison to that of the ®ve amino acid deleted dHGF isoform (723 amino acid isoform) has not been previously reported. To examine the mRNA abundance of the HGF isoforms, RT ± PCR analysis was performed on total RNA prepared from various tissues and cell types. We were able to distinguish between the two isoforms of HGF based on the 15 base pair size dierence in the PCR products when fractionated by agarose gel electrophoresis (Figure 1c) . PCR using dHGF and HGF control cDNAs independently resulted in strong products of the appropriate size ( Figure 1c, lanes 11 and 12) . However, when both templates were included in the same reaction, slower migrating artifactual bands arose which do not appear to alter the ratio of the expected products ( Figure 1c , lane 10). Evaluation of the ratio of dHGF/HGF mRNAs expressed in normal mouse tissues revealed that both isoforms are expressed in parallel with the full-length isoform being highly prevalent. However, in our ALB-dHGF transgenic mice, the mRNA for the dHGF isoform is overexpressed in the liver as compared to the non-transgenic littermates ( Figure  1c , lane 4 vs lane 9). As expected, the albumin promoter directed transgene expression solely to hepatocytes (Figure 1c, lane 5) . Hepatocytes express the HGF/dHGF receptor, Met, but do not normally express HGF. Therefore, we have eectively established an autocrine growth system within the dHGF transgenic hepatocytes.
Growth promoting eect of dHGF both in vitro and in vivo
To demonstrate that a dHGF autocrine loop is intact and that the transgenic dHGF protein is functional, we perfused transgenic and control mouse livers, isolated the hepatocytes and analysed them in cell culture. Conditioned media from primary hepatocyte cultures of dHGF transgenics exhibited high levels of scatter activity and stimulation of DNA synthesis in bioassays using primary rat hepatocytes indicating that they do secrete functional dHGF protein. This activity was inhibited with anti-HGF antibody (data not shown).
To further con®rm that the dHGF autocrine loop induces hepatocyte proliferation in vivo we examined DNA synthetic activity by examining the amount of BrdU incorporated into transgenic and non-transgenic mouse livers following 1/3 partial hepatectomy (PHX). dHGF transgenic animals exhibited a roughly twofold higher BrdU labeling index in comparison to nontransgenic littermate controls throughout 72 h of liver regeneration following PHX (Figure 2 ). Liver regeneration occurred in nearly half of the time in dHGF transgenics as compared to non-transgenic littermates based on liver/body weight ratios (data not shown). Thus, it is apparent that dHGF-transgenic hepatocytes possess a functional autocrine loop which gives them an enhanced growth capability both in vitro and in vivo. It is important to point out, however, that dHGF- RT ± PCR analysis of transgenic (lanes 1 ± 6) and non-transgenic (lanes 7 ± 9) mouse tissue mRNAs for endogenous HGF/dHGF and the dHGF transgene. HGF and dHGF cDNAs served as positive controls and water served as a negative control. When both HGF and dHGF templates were present in the reaction (lane 10), slower migrating artifactual bands resulted (lanes 1 ± 10). NPC, non-parenchymal liver cells; h-GH, human growth hormone transgenic and normal mice show no obvious dierences in liver/body weight ratio under normal conditions. Hence, the eects of overexpression of dHGF are likely to be seen only under stressful pathophysiologic conditions such as PHX, liver injury/disease or hepatotoxin administration.
Enhanced development of hepatocellular carcinomas in dHGF transgenic mice
Transgenic mice sacri®ced at 1 ± 17 months of age showed no apparent phenotypic dierences from nontransgenic littermates. However, beyond 17 months of age, male dHGF transgenic mice were three times more likely to develop HCCs than their normal littermate controls (Table 1) . Only 11% (8/69) of all nontransgenic male mice had grossly visible macroscopic liver tumors (HCC), where as 31% (15/49) of all dHGF-transgenic males exhibited such tumors. Interestingly, we also found spontaneous HCCs in dHGF transgenic female mice which is noteworthy since females are notoriously resistant to HCC (Table 1) . In addition to the higher incidence of HCCs, the overall size of these tumors in dHGF-transgenic mice was signi®cantly larger. Conversely, the incidence of other types of tumors such as hemangiosarcomas and lymphomas was not signi®cantly dierent in dHGFtransgenic and non-transgenic litter mates. These results suggest that the increased carcinogenesis observed in transgenic hepatocytes is due to stimulation by the dHGF autocrine loop.
To further investigate the role of dHGF as a growth promoter of HCC, we initiated HCC tumorigenesis in 15 day old transgenic and non-transgenic litter mates by a single i.p. injection of diethylnitrosamine (DEN), a known liver carcinogen. At 12 weeks of age equivalent numbers of low grade adenomatous foci were evident in liver sections of both transgenic and non-transgenic mice. However, at 24 weeks after DEN administration, both dHGF-transgenic males and females possessed larger and more numerous foci than their non-transgenic counterparts many of which had progressed to HCC. This dierence was extremely evident by 40 weeks of age where 90% (8/9) of dHGFtransgenic female mice had frank HCC (macroscopic tumors 40.5 cm in diameter), whereas 0% (0/5) of non-transgenic female mice had such tumors ( Figure 3 and Table 1 ). At 40 weeks post-DEN, transgenic and wild-type males possessed multiple HCCs and numerous high grade hepatocellular adenomas. Similarly (Table  2) . We also found microvascular invasion and extrahepatic metastases (to the lung) in several DEN-treated dHGF-transgenic mice but not in non-transgenic. This implies that the tumors in dHGF transgenics may also be signi®cantly more invasive possibly due to their autocrine growth capabilities and the metastogenic properties of HGF. Nevertheless, these data indicate that dHGF plays an active role in promoting the growth of hepatocellular carcinoma.
Veri®cation of HGF involvement in promotion of HCC
HGF and dHGF exert their eects on target cells via the tyrosine kinase receptor, Met. Thus it follows that in order for dHGF to promote the growth of these tumors, they must express Met. Expression was con®rmed by Northern blot analysis which revealed that the majority of the HCCs (spontaneously evolved and carcinogen induced) express Met mRNA ( Figure  4a ). The level of Met mRNA expressed is consistently higher in transgenic livers than in wild-type livers. Most liver tumors expressed Met mRNA at levels equivalent to or in excess of normal mouse liver (Figure 4a) . Similarly, Northern blot analysis revealed that most tumors expressed the dHGF transgene mRNA at variable levels, higher in the tumors than in adjacent normal liver in some cases and lower in others. In addition, expression of the nuclear phosphoprotein, c-myc, whose overexpression is associated with HCC, was observed to be high in some but not all HCCs. Met protein expression in normal liver and HCCs was analysed by immunoprecipitation and immunoblotting with anti-Met antibody. Western blot analysis con®rmed that the functional p145 form of Met is expressed in these HCCs at a level comparable to adjacent normal liver (Figure 4b ). The Met protein expressed in these tissues is tyrosine phosphorylated (and presumably active) as evidenced by Western analysis using anti-phosphotyrosine antibody ( Figure  4b) . The fact that a dramatic increase in Met protein and kinase activity was not observed in transgenic liver and tumors may be the result of rapid turnover of the p145 Met protein presumably due to binding, internalization and degradation of the Met receptor (Chen et al., 1997) . Furthermore, immunohistochemical analysis of tumor bearing dHGF-transgenic liver sections showed that Met and HGF proteins are more highly expressed in many tumor cells than in adjacent normal liver ( Figure 5 ). Similar Met and HGF immunoreactivity was observed in the tumor tissues of non-transgenic animals (data not shown). These ®ndings suggest that dHGF and Met are actively involved in growth promotion of HCC.
To further examine the growth characteristics as well as dHGF and Met gene expression in these HCCs, we isolated and established several tumor cell lines from the dHGF transgenic tumors. These HCC cell lines grew very quickly, maintaining a doubling time of approximately 24 h and exhibited a scattered morphology reminiscent of hepatocyte cultures grown in the presence of HGF (data not shown). These cell lines express very high levels of Met mRNA and modest levels of the dHGF transgene mRNA in cell cultures and are truly of hepatic origin based on their expression of albumin ( Figure 6 ). Preliminary experiments involving addition of antisense-oligonucleotides to Met mRNA (from 73 to +18 bp relative to the translation start site) resulted in the inhibition of the growth of these cells by nearly 50%. Future studies with these cell lines will give valuable insight into the mechanism of HCC growth promotion by dHGF. 
Discussion
Hepatocyte growth factor (HGF) induces mitogenesis, motogenesis, morphogenesis and anti-apoptotic signals in hepatocytes and is essential for liver growth during embryonic development. The HGF gene is expressed in the liver as two isoforms called HGF and dHGF (the ®ve amino acid deleted type) arising by alternative splicing of the HGF primary RNA transcript. The role of the dHGF isotype in liver growth and carcinogenesis has not been described. In the current study, we have addressed this issue by directing dHGF expression to the liver of transgenic mice. One of the most important ®ndings from our study is that the ®ve amino acid deleted isoform of HGF (dHGF) acts as a strong promoter of hepatocellular carcinoma growth in vivo. Secondly, we found that dHGF enhances liver regeneration in this transgenic model.
In general, it is believed that growth factors act during multiple stages of tumorigenesis particularly promotion and progression. Our results suggest that dHGF acts as tumor promoter and progressor because dHGF-transgenic mice develop spontaneous HCC late in life in a stochastic manner (beyond 17 months of age at a rate of 31%) indicating that other genetic and epigenetic events such as activation of oncogenes and inactivation of tumor suppressor genes must occur prior to the time that the eects of dHGF overexpression are manifested. Interestingly, we have observed that expression of endogenous dHGF mRNA is elevated in several liver tumors of wild-type mice. These data suggest that dHGF is intimately involved in the growth and progression of hepatocellular tumors.
Cooperation among the products of various genes like growth factors and nuclear transcription factors during hepatocarcinogenesis has been well-documented in several transgenic mouse models. For example, overexpression of the murine c-myc transgene in liver causes HCC in 40% of the transgenic mice at 15 months of age. However, when these mice were crossed with transgenic mice overexpressing epidermal growth factor in the liver, the resulting hybrid animals developed HCC by 5 months of age (Tonjes et al., 1995) . Similarly, transgenic mice overexpressing transforming growth factor alpha (TGFa) in the liver developed HCC late in life, but hepatocarcinogenesis was dramatically accelerated in double transgenic mice overexpressing TGFa and c-myc in the liver (SantoniRugiu et al., 1996a) .
The tumor promoting eects of dHGF became more apparent when the dHGF-transgenic mice were initiated with a liver carcinogen (DEN) which causes genetic mutations. Once`initiated', cells may live and accumulate more mutations or die via apoptosis. dHGF-transgenic mice have an innate gain-of-function mutation in the form of a growth stimulating autocrine loop in hepatocytes, which normally express Met. For this reason, tumor foci in dHGF transgenic mice may be more apt to survive and progress to large tumors as compared to those in non-transgenic littermates. Although the incidence of initiated cells (as evidenced by the number of microscopic foci) in non-transgenic mice at 12 weeks post DEN treatment was the same as in dHGF transgenics, fewer foci survived in non-transgenic mice to become large tumors. This may be explained by the ®nding that the HGF/Met signaling system not only induces mitogenesis but also promotes cell survival through an anti-apoptotic eect (Tamagnone and . Indeed, transgenic mice overexpressing the intracellular domain of the HGF receptor in the liver (hepatocytes) were found to be highly resistant to apoptosis-inducing agents such as anti-Fas antibody (Amicone et al., 1997) .
Although the role of the HGF gene product(s) in growth of normal hepatocytes during embryonic development Maina et al., 1996; Schmidt et al., 1995; Uehara et al., 1995) has been wellestablished through gene knock out studies, the literature on the function of this growth factor with regard to stimulation of HCC growth is somewhat contradictory (Johnson et al., 1995; Sakata et al., 1996; Santoni-Rugiu et al., 1996b; Shiota et al., 1994 Shiota et al., , 1996 . It has been reported that overexpression of the human full-length HGF isoform under the transcriptional regulation of the albumin promoter/enhancer in transgenic mice (FVB genetic background) does not result in HCC development (Shiota et al., 1994) . Moreover, when these transgenic mice were cross bred to transgenic mice overexpressing the c-myc transgene in the liver, a dramatic inhibition of hepatocarcinogenesis occurred in the resulting hybrids (Santoni-Rugiu et al., 1996b) . The apparent dierence in their ®ndings as compared to our current results may be explained, at least in part, by the following: (1) we used the ®ve amino acid-deleted isoform of HGF which has not been thus far evaluated for its tumorigenic potential; and (2) the genetic background of the mice (B6D2) used in our experiments are apparently much more susceptible to hepatocarcinogenesis (10% of the nontransgenic males spontaneously developed HCC beyond 17 months of age) whereas those used in the previous studies (FVB strain) were rather resistant (0% spontaneously developed tumors) (Shiota et al., 1994) . Another recent study of transgenic mice overexpressing the full-length isoform of HGF under the transcriptional regulation of the metallothionein promoter/ enhancer (which directed HGF transgene expression to a wide variety of tissues), however, found accelerated hepatocarcinogenesis in old animals (Sakata et al., 1996) . In these transgenic mice, the authors also observed drastic embryonic and postnatal developmental abnormalities and tumorigenesis in several other tissues . Likewise, our dHGF transgenic model exhibited enhanced HCC tumorigenesis; however, we observed no other signi®cant alterations in embryonic or postnatal development even up to 24 months of age.
Interestingly, past hepatocarcinogenesis studies involving administration of exogenous HGF/dHGF have also yielded contradictory results. Previously, Liu et al. (1995) found that short term administration of exogenous dHGF to rats bearing established DENinitiated tumors resulted in suppression of DNA synthesis in the tumors whereas, Yaono et al. (1995) found that multiple injections of exogenous HGF into rats previously initiated with DEN resulted in enhanced development of preneoplastic foci. The latter supports our ®ndings which show that dHGF indeed promotes the growth and progression of HCC.
Our study also demonstrated that the ®ve amino acid deleted isoform plays a role in liver regeneration as compared to non-transgenic littermates. We challenged the dHGF-transgenic mice with partial hepatectomy, since it is believed that hepatocytes will only respond to growth factors when they are in à primed' state, having switched from G0 to G1 phase of the cell cycle, as a result of a loss of liver parenchyma (Roos et al., 1995; Webber et al., 1994) .
Using RT ± PCR, we also found that endogenous dHGF is expressed in normal liver as well as in HCC tissues in non-transgenic animals thus suggesting that dHGF is a biologically relevant molecule and that the dHGF-transgenic mice we have generated provide a suitable model system for further investigating the functions of dHGF in vivo.
Materials and methods
dHGF transgenic mice
A 2.3 kb human HGF cDNA containing the entire coding region for the deleted isoform, dHGF, cloned from a human placental cDNA library (Wolf et al., 1991) was inserted into the BamHI site of an albumin promoterdriven expression vector ( Figure 1a ) which was kindly provided by Dr R Palmiter (University of Washington, USA). This transgene was used to generate transgenic mice by established methodism (Hogan et al., 1986) using the mouse strain B6D2 (C57B66DBA2). One of these transgenic lines produced was utilized for this study based on its high transgene expression. Transgenic mice were identi®ed by Southern blot analysis of EcoRI digested genomic tail DNA using a 32 P-labeled 2.3 kb dHGF cDNA probe. Hybridization conditions were as described elsewhere (Liu et al., 1994a) . To con®rm Southern results, PCR analysis of blood DNA was performed (Kawasaki, 1990 ) using oligonucleotide primers designed from the HGF gene (Chen et al., 1997) .
Transgenic mice were propagated by breeding with wildtype (B6D2) mice. All animal studies were performed in accordance with the guidelines of the Institutional Animal Use and Care Committee of the University of Pittsburgh.
dHGF RT ± PCR analysis
Reverse transcription was performed using 1 mg RNA, avian myeloblastosis virus reverse transcriptase (Boehringer Mannheim) and random hexamers followed by ampli®cation with Taq DNA polymerase (Boehringer Mannheim) as per the manufacturer's instructions using HGF/dHGF speci®c primers (sense, 5'-GGCCAT-GAATTTGACCTCTATGAA-3' and antisense, 5'-TTCAACTTCTGAACACTGAGGAAT-3'). The primers are oriented on opposite sides of the 15 bp deletion found in dHGF and thus give a 278 bp product for dHGF and a 293 bp product for full length HGF. RT ± PCR was also performed without reverse transcriptase to ensure that no genomic DNA contamination was present.
BrdU incorporation and labeling indices
Six mice per time point (3 dHGF-TG, 3 NTG) were subjected to 1/3 partial hepatectomy (PHX) and sacri®ced at various times thereafter. A single injection of 20 mg/ml BrdU (Boehringer Mannheim) in a dose of 50 mg/kg was administered 2 h prior to sacri®ce. Livers were excised, and representative sections from each lobe were ®xed and stained with anti-BrdU antibody. Positively staining hepatocyte nuclei were counted in 15 random ®elds per animal (2006 magni®cation) and plotted as the mean+s.e.m.
Carcinogen-induced HCC
At 15 days of age, mice were given a single i.p. injection of diethylnitrosamine (DEN) (Sigma Chemical Co.) in a dose of 5 mg/g of body weight. At 21 days of age, mice were separated by sex and their transgenicity was determined. At 12 and 24 weeks of age, a minimum of two animals per group were sacri®ced and analysed as stated below. At 40 weeks of age, all remaining animals were sacri®ced and analysed (3 ± 9 animals per group). Representative sections from each lobe of the liver and visible tumors were ®xed, sectioned, stained with hematoxolin and eosin (H&E) and examined for the presence of adenomas and HCCs. Hepatocellular adenomas and carcinomas were scored based on the following criteria: absence of bile ductules, aberrant hepatic arterioles, mitoses, high nuclear : cytoplasmic ratio, hyperchromasia, irregular nuclear contour, nuclear density, existence of large cells and vascular invasion (Nakanuma et al., 1993; Wanless, 1990) . Focal areas of HCC were visualized, counted and measured at 2006 magni®cation using an Olympus Vonox AHBT3 microscope (Olympus Optical Co. Ltd) with Optimas 1.0 software program (Optimas Co.). Estimations of the total number of microscopic HCC foci/cm 3 were calculated using the methods of Pugh et al. (1983) described elsewhere. Statistical analysis of tumor incidence and size was carried out using the Student t-test.
Analysis of tissues and tumors
For morphological, immunohistochemical and molecular analysis, liver, kidney, lung, spleen and all tumor tissues were grossly examined and excised from mice sacri®ced between 18 and 26 months of age. A portion of each tissue or tumor was snap frozen in liquid nitrogen or ®xed in 10% buered formalin. From some animals, hepatocytes and non-parechymal liver cells were isolated by in situ perfusion of the liver with collagenase (Boehringer Mannheim) and cultured for in vitro studies (Zarnegar and Michalopoulos, 1989) . For histologic determinations, all ®xed tissues were embedded in paran, sectioned and stained with H&E. For immunohistochemical experiments, sections were stained with goat anti human HGF polyclonal antibody (R&D Systems) or rabbit anti mouse c-met polyclonal antibody (Santa Cruz Biotechnology) using a basic immunochemistry protocol described previously by Chen et al. (1996) . All samples subjected to immunohistochemical studies also received routine histologic examination with hematoxylin and eosin staining.
RNA isolation and Northern blot analysis
Tissue and cell line RNAs were isolated using RNAzol B (Cinna/Biotecx, Friendswood, TX, USA) as per the manufacturer's instructions. Total RNA (20 mg/lane) was electrophoresed on formaldehyde containing 1% agarose gels, transferred to GeneScreen Plus membranes (NEN Life Science Products) and hybridized as described elsewhere (Liu et al., 1994b) . The 32 P-labeled probes used were (i) the full length 2.3 kb human HGF cDNA, (ii) a 836 bp mouse Met cDNA probe generated by RT ± PCR of mouse liver RNA using the following set of primers: sense: 5'-GCAGAAACCCCCATCCAGAATGTC-3' and antisense: 5'-GGCCCCTGGTTTACTGACATACGC-3', (iii) a 500 bp PstI fragment of the rat c-myc cDNA (kindly provided by Dr J Locker, University of Pittsburgh School of Medicine), and (iv) the rat albumin cDNA as a normalization control (kindly provided by Dr S Strom, University of Pittsburgh School of Medicine). After hybridization, the membranes were washed and exposed to autoradiography ®lm (Fuji).
Immunoprecipitation and Western blot analysis
Met protein was immunoprecipitated from 1 mg total protein from each sample and subjected to SDS ± PAGE as described elsewhere (Rong et al., 1993) . After transfer to Imobilon P membranes, blots were blocked and then incubated with anti-Met antibody (Santa Cruz Biotechology) or anti-phosphotyrosine antibody (Transduction Laboratories) as per the manufacturer's instructions.
Reactions were visualized using a Renaissance enhanced chemiluminescence system (NEN Life Science Products).
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